title: [Cutaneous radiation syndrome after accidental skin exposure to ionizing radiation].
abstract: Accidental exposure of the human skin to single doses of ionizing radiation greater than 3 Gy results in a distinct clinical picture, which is characterized by a transient and faint erythema after a few hours, then followed by severe erythema, blistering and necrosis. Depending on severity of damage, the latter generally occurs 10-30 days after exposure, but in severe cases may appear within 48 hrs. Between three and 24 months after exposure, epidermal atrophy combined with progressive dermal and subcutaneous fibrosis is the predominant clinical feature. Even years and decades after exposure, atrophy of epidermis, sweat and sebaceous glands; telangiectases; and dermal and subcutaneous fibrosis may be found and even continue to progress. For this distinct pattern of deterministic effects following cutaneous accidental radiation exposure the term "cutaneous radiation syndrome (CRS)" was coined in 1993 and has been accepted by all international authorities including IAEA and WHO since 2000. In contrast to the classical concept that inhibition of epidermal stem cell proliferation accounts for the clinical symptomatology, research of the last three decades has demonstrated the additional crucial role of inflammatory processes in the etiology of both acute and chronic sequelae of the CRS. Therefore, therapeutic approaches should include topical and systemic anti-inflammatory measures at the earliest conceivable point, and should be maintained throughout the acute and subacute stages, as this reduces the need for surgical intervention, once necrosis has occurred. If surgical intervention is planned, it should be executed with a conservative approach; no safety margins are needed. Antifibrotic measures in the chronic stage should address the chronic inflammatory nature of this process, in which over-expression TGF beta-1 may be a target for therapeutic intervention. Life-long follow-up often is required for management of delayed effects and for early detection of secondary malignancies, which must be searched for especially in the borderline areas between clinically symptomatic and asymptomatic skin.
authors: Capio Blausteinklinik, Gefäß- und Hautzentrum, Erhard-Grözinger-Str. 102, 89134, Blaustein/Ulm, Deutschland, ralf.peter@de.capio.com.
authors: R U
authors: RU
authors: Peter
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D004781:Environmental Exposure / Q000009:adverse effects; D006801:Humans; D011829:Radiation Dosage; D011832:Radiation Injuries / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D011839:Radiation, Ionizing; D018788:Radioactive Hazard Release; D011855:Radiodermatitis / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D012867:Skin / Q000528:radiation effects*; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy*; D013577:Syndrome
chemical_list: D000893:Anti-Inflammatory Agents